Friday July 24, 2026
Section

KoreWire

Sarcomatrix Therapeutics Opens Accredited Investor Round for Once-Daily Pill Designed to Address Duchenne Regardless of Genetic Mutation
Press Release

Sarcomatrix Therapeutics Opens Accredited Investor Round for Once-Daily Pill Designed to Address Duchenne Regardless of Genetic Mutation

There are more than 30 types of muscular dystrophy and over 7,000 known mutations in the Duchenne gene alone, which has

Read Full Story